Literature DB >> 18297282

CD54 is a surrogate marker of antigen presenting cell activation.

N A Sheikh1, L A Jones.   

Abstract

There is no single universally accepted hallmark of antigen presenting cell (APC) activation. Instead a variety of methods are used to identify APCs and assess their activation state. These activation measures include phenotypic methods [e.g., assessing the increased expression of surface markers such as major histocompatability (MHC) class II] and functional assays (e.g., evaluating the enhanced ability to take up and process antigen, or stimulate naïve T cells). Sipuleucel-T is an investigational autologous active cellular immunotherapy product designed to stimulate a T cell immune response against human prostatic acid phosphatase (PAP), an antigen highly expressed in prostate tissue. Sipuleucel-T consists of peripheral blood mononuclear cells (PBMCs), including activated APCs displaying epitopes of PAP. In order to develop a robust reproducible potency assay that is not hampered by MHC restriction we have developed a method to simply assess the biological activation of antigen presenting cells (APCs). In the course of sipuleucel-T characterization, we analyzed various phenotypic and functional parameters to define the activation state of APCs obtained from peripheral blood. Flow cytometric assays revealed that CD54+ cells are responsible for antigen uptake, and that expression of CD54 predominantly localizes to APCs. Costimulation, as measured by an allogeneic mixed lymphocytic reaction (alloMLR) assay, showed that activity was restricted to the CD54+ cell population. Similarly, CD54+ cells harbor all of the PAP-specific antigen presentation activity, as assayed using a PAP-specific HLA-DRbeta1-restricted T cell hybridoma. Finally we show that CD54 expression is substantially and consistently upregulated on APCs during culture with a GM-CSF fusion protein, and that this upregulation activity can be quantified. Thus these data support the use of CD54 upregulation as a surrogate for assessing human APC activation and validates its utility as a potency measure of sipuleucel-T.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297282     DOI: 10.1007/s00262-008-0474-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Authors:  Marijo Bilusic; Ravi A Madan
Journal:  Am J Ther       Date:  2012-11       Impact factor: 2.688

3.  Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling.

Authors:  Luciano Castiello; Marianna Sabatino; Yingdong Zhao; Barbara Tumaini; Jiaqiang Ren; Jin Ping; Ena Wang; Lauren V Wood; Francesco M Marincola; Raj K Puri; David F Stroncek
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

4.  A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

Authors:  Douglas G McNeel; Thomas A Gardner; Celestia S Higano; Philip W Kantoff; Eric J Small; Mark H Wener; Robert B Sims; Todd DeVries; Nadeem A Sheikh; Robert Dreicer
Journal:  Cancer Immunol Res       Date:  2014-09-04       Impact factor: 11.151

5.  CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Authors:  Phillip D Fromm; Michael S Papadimitrious; Jennifer L Hsu; Nicolas Van Kooten Losio; Nirupama D Verma; Tsun Ho Lo; Pablo A Silveira; Christian E Bryant; Cameron J Turtle; Rebecca L Prue; Peter Vukovic; David J Munster; Tomoko Nagasaki; Ross T Barnard; Stephen M Mahler; Sébastien A Anguille; Zwi Berneman; Lisa G Horvath; Kenneth F Bradstock; Douglas E Joshua; Georgina J Clark; Derek N J Hart
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 6.  Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

Review 7.  Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Authors:  Lisa H Butterfield; A Karolina Palucka; Cedrik M Britten; Madhav V Dhodapkar; Leif Håkansson; Sylvia Janetzki; Yutaka Kawakami; Thomas-Oliver Kleen; Peter P Lee; Cristina Maccalli; Holden T Maecker; Vernon C Maino; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Graham Pawelec; Douglas M Potter; Licia Rivoltini; Lupe G Salazar; Dolores J Schendel; Craig L Slingluff; Wenru Song; David F Stroncek; Hideaki Tahara; Magdalena Thurin; Giorgio Trinchieri; Sjoerd H van Der Burg; Theresa L Whiteside; Jon M Wigginton; Francesco Marincola; Samir Khleif; Bernard A Fox; Mary L Disis
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

Review 8.  The evolving role of immunotherapy in prostate cancer.

Authors:  Lisa M Cordes; James L Gulley; Ravi A Madan
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

9.  Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO.

Authors:  Tina L Sumpter; Anil Dangi; Benjamin M Matta; Chao Huang; Donna B Stolz; Yoram Vodovotz; Angus W Thomson; Chandrashekhar R Gandhi
Journal:  J Immunol       Date:  2012-09-07       Impact factor: 5.422

10.  Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells.

Authors:  S P Shaha; J Tomic; Y Shi; T Pham; P Mero; D White; L He; J L Baryza; P A Wender; J W Booth; D E Spaner
Journal:  Clin Exp Immunol       Date:  2009-07-17       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.